AstraZeneca

News

AZ resumes UK coronavirus vaccine trial

AstraZeneca has resumed UK trials for its coronavirus vaccine, after the country's medicines regulator gave the all-clear following a safety scare.

News

AstraZeneca's (AZ) Tagrisso (osimertinib)

Price cut wins NICE OK for AZ’s Tagrisso in untreated lung c...

UK cost-effectiveness watchdog NICE has changed its stance on AstraZeneca’s Tagrisso as a first-line therapy for non-small cell lung cancer (NSCLC) after an improved “commercial arrangement

News

AZ's COVID-19 vaccine trial pause a 'wake-up call' - WHO

AstraZeneca’s pause of its COVID-19 vaccine trial is a “wake-up call” demonstrating the challenges of the development process, according to the World Health Organization’s chief scientist.<

News

AstraZeneca Amenities Building - Mississauga - Sept 2005
Non exclusive, unlimited time license for print & web to WZMH Architects

AZ's Fasenra on target in nasal polyps trial

AstraZeneca’s Fasenra (benralizumab) injected drug cuts the size of nasal polyps and nasal blockage in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

News

AZ says COVID vaccine halt 'routine', as analysts debate the...

AstraZeneca’s decision to halt all its phase 3 trials of COVID-19 vaccine AZD1222 after an adverse reaction in a single UK volunteer may end up just being a precautionary measure, but could

News

AZ halts COVID-19 vaccine after safety scare, as UK faces 's...

It’s a bleak day in the fight against COVID-19, after the UK banned social gatherings of more than six people to contain growing numbers of new cases and the lead vaccine trial from AstraZe

AZ resumes UK coronavirus vaccine trial

Price cut wins NICE OK for AZ’s Tagrisso in untreated lung c...

AZ's COVID-19 vaccine trial pause a 'wake-up call' - WHO

AZ's Fasenra on target in nasal polyps trial

AZ says COVID vaccine halt 'routine', as analysts debate the...

AZ halts COVID-19 vaccine after safety scare, as UK faces 's...

Making direct-to-patient work, with Matt Wadyka

Using AI-driven synthetic personas to take your insights fur...

AstraZeneca

Editor's Picks